Navigation Links
All-Oral Combination Study with PSI-7977 for HCV Genotypes 1, 2 and 3 Initiated
Date:5/26/2011

Act of 1995: Statements in this press release that are not historical facts are "forward-looking statements," that involve risks, uncertainties, and other important factors, including, without limitation, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of risks, uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended September 30, 2010 and our Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
2. Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
3. Nexavar in Combination with Chemotherapy Improves Progression-Free Survival in Patients with Advanced Breast Cancer in Phase 2 Study
4. ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor
5. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
6. Particle Sciences and Celanese EVA Performance Polymers Collaborate to Accelerate Drug-Eluting Device Combinations
7. Jennerex and Green Cross Announce Publication of Positive Clinical Data of JX-594 in Combination With Sorafenib in Advanced Liver Cancer
8. Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients
9. New Interim Data About Combination Oral Contraceptives
10. Syndax Announces Start of NCI Sponsored Phase 2 Study of Entinostat in Combination in Triple Negative Breast Cancer
11. Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... DRRX ) announced today financial results for the second ... loss was $5.5 million for the three months ended June ... and net loss of $5.5 million for the three months ... and investments of $37.8 million, compared to cash and investments ... 2015, we had $19.8 million in long term debt. ...
(Date:8/3/2015)... PARSIPPANY, N.J. , Aug. 3, 2015  LEO ... and Drug Administration (FDA) to include psoriasis as one ... Focused Drug Development Initiative i .  Psoriasis is an ... lives and subsequent comorbidities, affecting 7.5 million people in ... of LEO Pharma,s ongoing commitment to supporting patients living ...
(Date:8/3/2015)... N.Y. , Aug. 3, 2015 ... Wilmot Cancer Institute to the OmniSeq SM ... Roswell Park Cancer Institute (RPCI) and announced it ... that support a physician-driven, collaborative approach to genomic ... outcomes.  Wilmot Cancer Institute is a rapidly expanding, ...
Breaking Medicine Technology:DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 2DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 3DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 4DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 5DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 6DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 7DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 8DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 9DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 10LEO Pharma Supports the FDA's Selection of Psoriasis as a Priority Disease 2LEO Pharma Supports the FDA's Selection of Psoriasis as a Priority Disease 3OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 2OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 3
... Researchers at Brigham and Women,s,Hospital found that patients taking ... effects were unrelated to relief from their pain,symptoms. ... examine the addictive,potential of this class of pain medicine, ... 25th Annual Meeting. , In ...
... Lethal ,Super, Strains of C.difficileCHICAGO, Jan. 28 ... scientists at The University of Nottingham are leading a ... one of the most lethal strains of hospital acquired ... technology developed in Nottingham to study the function of ...
Cached Medicine Technology:Study of Cannabinoid Medicine for Pain Found Patients Got 'High,' but Effects Not Related to Pain Relief 2British Midlands University Announces Use of Gene Technology to Fight Lethal Hospital Acquired Infection 2British Midlands University Announces Use of Gene Technology to Fight Lethal Hospital Acquired Infection 3
(Date:8/4/2015)... ... August 04, 2015 , ... ... other long-term care facilities, today announced details of the Advanced level of their ... centers. , Providigm’s QAPI Accreditation program , introduced in 2013, is based ...
(Date:8/4/2015)... Vegas, Nevada (PRWEB) , ... August 04, 2015 ... ... FEMALE, a striking contemporary look at unique artistic expressions from a diverse group ... inside the Life Is Beautiful Music & Art Festival on September 25-27, 2015 ...
(Date:8/4/2015)... D.C. (PRWEB) , ... August ... ... that its HealthCenter personal health record (PHR) product has achieved Office of ... and Inpatient EHR Certification from Drummond Group. HealthCenter delivers the highest quality ...
(Date:8/4/2015)... ... August 04, 2015 , ... Driving skills may ... to driving, says the August 2015 Harvard Health Letter. , "Age and health ... requires an individual assessment of skills," says Lissa Kapust, a social worker at ...
(Date:8/4/2015)... ... August 04, 2015 , ... METTLER TOLEDO has announced ... featuring researchers from Lubrizol, Pfizer, and Merck. This free online seminar will ... project timelines often require informed decisions with limited process understanding. Established methods ...
Breaking Medicine News(10 mins):Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 2Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 3Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 2Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 3Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 4Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 2Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 3Health News:Assessment Can Help Older Drivers Keep Driving Safely, from the August 2015 Harvard Health Letter 2Health News:METTLER TOLEDO Announces New Process Chemistry and Scale-up Online Seminar 2
... ... conducted by the US Department of Health and Human Services. , ... Austin, TX (PRWEB) September 25, 2009 -- RCRC Independent ... will provide oversight of research supported or conducted by a federal department or agency within ...
... and weight are shaped by their social class, according to ... Policymakers have long insisted on the importance of ... the first study to show how everyday practices and perceptions ... weight and health of teenagers. ,It is evident that ...
... says it will review procedure for endorsing medical devices ... Food and Drug Administration violated procedures last year when ... own scientists recommended against approval, agency officials said Thursday. ... Jersey-based ReGen Biologics and is used to help surgically ...
... SAN FRANCISCO, CA SEPTEMER 24, 2009 Results ... that the combination of giving patients clopidogrel, a blood ... stomach medicines such as omeprazole, known as proton pump ... some prior studies had suggested. The results were presented ...
... , , NEW YORK, Sept. ... Ashoka will partner to create the first international fellowship program ... improve maternal health in developing countries. The Maternal Health Task ... Maternal Health Program as a commitment to action at the ...
... , , , ... Health Registry is expanding its service area across Oklahoma by partnering ... Web service on November 1st, 2009. , , ... has nearly doubled from 1.3 million people served by the Emergency ...
Cached Medicine News:Health News:RCRC Independent Review Board Announces DHHS Research Oversight 2Health News:Social background weighs heavily on teenage diet 2Health News:FDA Acknowledges Mistakes in Knee-Device Approval 2Health News:Cogent trial shows lack of adverse interaction between clopidogrel and stomach medicine 2Health News:Building the Next Generation of Global Leaders - Maternal Health Task Force and Ashoka Partner 2Health News:Building the Next Generation of Global Leaders - Maternal Health Task Force and Ashoka Partner 3Health News:Oklahoma Medics Embracing iB Web Service 2
... FDA-cleared third-generation allergy test , 3gAllergy is ... It provides quantitative determination of allergen-specific IgE ... accuracy and lot-to-lot reproducibility. The assay delivers ... help you identify, monitor and manage patients ...
The 6.5mm cannulated cancellous ACE SCFE Screw is specifically designed for the treatment of slipped capital femoral epiphysis. The ACE SCFE Screw simplifies insertion and facilitates removal....
Smith & Nephew offers a wide variety of cannulated screw products. Most screw sizes are available in both partially threaded and fully threaded versions. , ,All systems optimize implant strength with...
... Retrograde Humeral Nail enables fixation of humeral ... that may be associated with antegrade nailing. ... and distal interlocking using a nail-mounted targeting ... interlocking with the patient in the prone ...
Medicine Products: